UK Markets closed

Basilea Pharmaceutica AG (0QNA.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
49.74+0.46 (+0.92%)
At close: 05:41PM GMT

Basilea Pharmaceutica AG

Grenzacherstrasse 487
Basel 4058
Switzerland
41 61 606 11 11
https://www.basilea.com

Sector(s)
Industry
Full-time employees177

Key executives

NameTitlePayExercisedYear born
Mr. David VeitchChief Exec. Officer1.11MN/A1965
Mr. Adesh KaulChief Financial OfficerN/AN/A1974
Dr. Gerrit Hauck Ph.D.Chief Technology OfficerN/AN/A1964
Dr. Laurenz Kellenberger Ph.D.Chief Scientific OfficerN/AN/A1967
Dr. Marc Engelhardt M.D.Chief Medical OfficerN/AN/A1964
Dr. Peer Nils SchroderHead of Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Damian HellerGen. Counsel & Corp. Sec.N/AN/A1966
Ms. Ursula EberhardtHead of Global HRN/AN/A1962
Mr. Lutz WevelsiepHead of Regulatory AffairsN/AN/AN/A
Mr. Dietrich StüberHead of Internal ServicesN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

Corporate governance

Basilea Pharmaceutica AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.